Skip to content
Drug Policy Watch™
LatestTracking drug policy in all 50 states and Congress, updated every morning.See all ›
Drug Policy Watch · State Brief 2026

Alaska

Snapshot (structured)

Adult-use cannabis
Legal since 2014 (Ballot Measure 2), retail sales since 2016
Medical cannabis
Legal since 1998 (Ballot Measure 8), registry-based, no licensed dispensary channel
Home grow
Legal, up to 6 plants per adult 21+ (no more than 3 mature), 12 per household
Intoxicating hemp / hemp THC
Restricted; intoxicating hemp THC (delta-8, HHC, etc.) routed through AMCO-licensed marijuana retailers only; court-upheld
Psychedelics
Illegal; state task force studying FDA-approved psychedelic medicines; 2026 ballot push failed, refocused on 2028
Broad decriminalization
No broad decriminalization of other drugs
Harm reduction
Naloxone and fentanyl test strips distributed statewide; syringe services operate but not expressly authorized in statute
Governor (party)
Mike Dunleavy (Republican)
Legislature control
Bipartisan/multipartisan coalitions lead both chambers; Republicans hold numerical majorities
Citizen ballot initiatives allowed
Yes (indirect initiated statutes)
Enclosure pressure score
2/5

Cannabis

Adult-use cannabis has been legal in Alaska since voters passed Ballot Measure 2 in November 2014, with licensed retail sales beginning in 2016. Adults 21 and older may possess up to one ounce in public and purchase from licensed retailers. Medical cannabis has been legal since 1998 under Ballot Measure 8, but Alaska never built a licensed medical dispensary system, so registered medical patients buy through the same adult-use retail stores. (Sources: https://www.mpp.org/states/alaska/ , https://alaskastatecannabis.org/laws )

Home cultivation is legal without a license. Each adult 21 or older may grow up to six plants, with no more than three mature/flowering at a time, and a household with two or more adults may grow up to 12 plants (no more than six mature). (Source: https://alaskastatecannabis.org/laws )

Market structure favors local ownership. Alaska is an open-license state with no statewide cap on the number of establishments, though local governments may impose their own limits or opt out. Every owner with a financial interest must be an Alaska resident eligible for the Permanent Fund Dividend, which effectively bars multi-state operators (MSOs) and out-of-state corporate capital. Vertical integration is permitted, with the exception that testing licensees may not hold other license types. The current excise tax is a wholesale cultivation tax of $50 per ounce on mature flower (with lower rates for other plant parts), one of the heavier producer-side tax structures in the country. (Sources: https://alaskacannabis.org/business/starting-a-cannabis-business , https://www.commerce.alaska.gov/web/amco/marijuanafaqs.aspx , https://www.adn.com/politics/alaska-legislature/2026/03/02/alaska-lawmakers-consider-statewide-marijuana-sales-tax/ )

Key 2026 actions center on tax relief (HB 91) and record sealing (folded into HB 239). See Active legislation below.

Hemp

Alaska treats intoxicating hemp tightly. Under AMCO amendments to 3 AAC 306 effective November 3, 2023, intoxicating hemp-derived cannabinoid products (delta-8 THC, HHC and similar) may be sold only through AMCO-licensed marijuana retailers rather than general retail. Delta-8 derived from hemp is otherwise treated as a controlled substance outside that channel. A federal court ruling in 2025 upheld the state's authority to confine these products to licensed marijuana stores. (Sources: https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/alaska-court-upholds-intoxicating-hemp-restrictions , https://www.cannabisregulations.ai/state-legality/alaska-hhc , https://area52.com/delta-8-thc-alaska/ )

On the federal side, the appropriations/shutdown legislation enacted in late 2025 narrowed the federal definition of "hemp" to cap total THC at 0.3 percent on a dry-weight basis, which closes the loophole that allowed high-delta-8 and similar products to qualify as hemp. That federal change takes effect around November 12, 2026. Because Alaska already restricts intoxicating hemp to the licensed marijuana channel, the state is less exposed to disruption than states with open intoxicating-hemp markets, but the federal definitional change will still tighten what can lawfully be produced or moved as "hemp." (Sources: https://perkinscoie.com/insights/update/shutdown-legislation-brings-new-hemp-rules , https://www.regulatoryoversight.com/2025/12/congress-narrows-federal-definition-of-hemp-effectively-banning-most-intoxicating-hemp-products/ , https://recovered.org/blog/federal-hemp-ban-legal-changes-2026 )

Psychedelics

Psychedelics remain illegal for general use in Alaska. The state has taken a study-first posture: HB 228, enacted in 2024, established the Alaska task force on the regulation of psychedelic medicines approved by the U.S. Food and Drug Administration, charged with preparing for potential medical access and recommending policy on licensure, insurance and implementation. (Source: https://chacruna.net/alaskas-natural-medicine-act-could-make-it-a-north-star-for-psychedelic-reform/ )

A citizen campaign launched a signature drive in 2025 for the Alaska Natural Medicine Act, a proposed ballot measure to decriminalize personal use of five compounds (psilocybin, psilocin, DMT, mescaline excluding peyote, and ibogaine), create regulated therapeutic access, and establish a Traditional Use Council recognizing Indigenous practice. In December 2025 the campaign announced it had not gathered enough signatures for the 2026 ballot and would refocus on 2028. No standalone psychedelics decriminalization bill is confirmed as advancing in the 2026 legislative session. (Sources: https://www.marijuanamoment.net/alaska-psychedelics-campaign-ends-push-to-put-legalization-on-2026-ballot-shifting-focus-to-2028/ , https://www.alaskasnewssource.com/2025/08/20/ballot-initiative-decriminalize-psychedelics-alaska-now-garnering-signatures/ )

Broader drug policy

Alaska has not enacted broad decriminalization of drugs beyond cannabis. On harm reduction, the Alaska Department of Health distributes large volumes of naloxone (more than 46,000 kits in a recent year) and fentanyl test strips (more than 89,000), and runs the Project HOPE naloxone program statewide. Syringe services programs operate (for example the Alaskan AIDS Assistance Association and a Homer-area program), but state law does not expressly authorize or prohibit SSPs, leaving them on uncertain statutory footing. (Sources: https://alaskabeacon.com/2024/05/07/as-alaska-overdose-deaths-mount-state-leaders-launch-new-education-effort/ , https://www.iknowmine.org/topic/harm-reduction/ )

On sentencing and expungement, the major 2026 development is the marijuana record-sealing provision folded into the omnibus crime bill HB 239 (see below), which lets qualifying low-level marijuana possession convictions be withheld from public release. Alaska historically has had very limited record-sealing/expungement, so this would be a meaningful narrow expansion. (Sources: https://norml.org/blog/2026/06/02/alaska-lawmakers-send-cannabis-record-sealing-bill-to-governors-desk , https://ccresourcecenter.org/state-restoration-profiles/alaska-expungment-pardon-sealing/ )

Political landscape

Governor Mike Dunleavy is a Republican. In the 34th Legislature (2025-2026), both chambers are run by bipartisan/multipartisan coalitions, an arrangement unique to Alaska. Republicans hold an 11-9 numerical edge in the Senate and a 21-14 edge (with five independents) in the House, but the Senate majority coalition contains all nine Democrats plus eight Republicans, and the House majority consists of 14 Democrats, five independents and two Republicans. This is the first time in Dunleavy's tenure that both chambers are led by Democrat-dominated coalitions. (Sources: https://ballotpedia.org/2026_Alaska_legislative_session , https://www.adn.com/politics/alaska-legislature/2024/11/26/incoming-bipartisan-alaska-house-and-senate-majorities-take-shape-with-similar-policy-goals/ )

Named reform champions: Rep. Ashley Carrick (D, Fairbanks) is leading cannabis tax reform via HB 91; Rep. David Nelson (R) advanced the marijuana record-sealing concept. Named opponents/skeptics: Gov. Dunleavy's office raised concerns that HB 239 "may not have received adequate deliberation" and said the bill needed careful analysis; he ultimately allowed it to become law without his signature on June 25, 2026, a posture of caution rather than confirmed opposition. Specific committee chairs driving these bills (House Finance, House Judiciary) are referenced in coverage but individual chair names are unconfirmed here. (Sources: https://www.adn.com/politics/alaska-legislature/2026/03/02/alaska-lawmakers-consider-statewide-marijuana-sales-tax/ , https://alaskapublic.org/news/politics/alaska-legislature/2026-05-20/alaska-legislature-passes-sweeping-crime-bill-raising-age-of-consent-to-18-on-last-day-of-session )

Ballot initiatives

Alaska allows citizen-initiated statutes (indirect initiative). To qualify for the ballot, sponsors must gather valid signatures equal to 10 percent of votes cast in the last general election (34,098 valid signatures for 2026), with signatures collected in at least 30 of the state's 40 House districts, and submitted before the start of the legislative session in January. Alaska does not allow citizen-initiated constitutional amendments. The leading drug-policy measure, the Alaska Natural Medicine Act (psychedelics), failed to gather enough signatures for 2026 and is now targeting 2028. No cannabis or drug-policy citizen measure is confirmed on the November 2026 ballot. (Sources: https://ballotpedia.org/Signature_requirements_for_ballot_measures_in_Alaska , https://ballotpedia.org/Alaska_2026_ballot_measures , https://www.marijuanamoment.net/alaska-psychedelics-campaign-ends-push-to-put-legalization-on-2026-ballot-shifting-focus-to-2028/ )

Equity and expungement

Alaska's cannabis statute does not contain a formal social-equity licensing program of the kind seen in some other states. The strongest equity-adjacent features are the in-state residency/Permanent Fund Dividend ownership requirement (which keeps ownership local but also excludes non-residents) and the home-grow allowance, which lowers barriers for personal cultivation. The 2026 record-sealing provision in HB 239 is petition-based, not automatic: qualifying individuals (21+ at the time, convicted only of possessing under one ounce, no other convictions in the same case) can request that agencies withhold the record from public release. It benefits a narrow class of low-level offenders and excludes anyone with co-occurring charges or larger amounts. (Sources: https://norml.org/blog/2026/06/02/alaska-lawmakers-send-cannabis-record-sealing-bill-to-governors-desk , https://alaskacannabis.org/business/starting-a-cannabis-business )

Market and barriers

Enclosure read

Alaska sits toward the open end of the spectrum. The residency/Permanent Fund Dividend ownership rule and the absence of a statewide license cap keep the cannabis market locally owned and block the MSO consolidation seen elsewhere, and home grow plus a study-first psychedelics posture keep individuals in the frame. The main fencing pressures are the heavy $50/oz producer tax (which squeezes small cultivators and which HB 91 aims to relieve), the channeling of intoxicating hemp exclusively through licensed marijuana retailers (which fences out general hemp/CBD sellers while protecting incumbent dispensaries), and the looming federal hemp redefinition. On balance the structure protects local operators more than it consolidates power, supporting a low-to-moderate score. Enclosure pressure score: 2/5.

What to watch next

  • Implementation of HB 239's marijuana record-sealing provision, which became law without Governor Dunleavy's signature on June 25, 2026.
  • Final status of HB 91 marijuana tax reform; a secondary source claims it became law, which is unconfirmed against primary records. If enacted, the excise cut is slated to begin July 2026.
  • The federal hemp definition change effective around November 12, 2026, and any AMCO conforming action.
  • The Alaska Natural Medicine Act campaign's pivot to the 2028 ballot and any psychedelics task force recommendations.
  • The 34th Legislature adjourned its regular session on May 20, 2026, with a special session called May 21, 2026 (gas line focus). The next regular session convenes in January 2027. (Sources: https://alaskabeacon.com/2026/05/21/alaska-legislature-adjourns-regular-session-with-special-gasline-session-set-for-thursday/ , https://ballotpedia.org/2026_Alaska_legislative_session )

Regulators

Federal exposure (2026)

Cannabis remains Schedule I by default at the federal level. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; recreational cannabis stays Schedule I. The broader DEA rescheduling hearing that opened June 29, 2026 is still pending and may slip to 2027. For Alaska this creates an awkward seam. Alaska legalized medical cannabis in 1998 but never built a licensed medical dispensary system, so registered patients buy through the same AMCO-licensed adult-use retail stores. There is no separate, state-licensed medical cannabis business category for the Schedule III order to attach to cleanly, the operators are recreational retailers serving medical patients on the side. The practical result is that Alaska's cannabis businesses are almost entirely on the recreational side of the line and get no relief from the order.

That matters most for 280E. The April 2026 change removed Internal Revenue Code Section 280E for state-licensed medical cannabis, but recreational operators, and anything still in Schedule I, keep getting hit with 280E (no deduction of ordinary business expenses, only cost of goods sold). Because Alaska's commercial channel is structured as adult-use retail rather than a distinct licensed medical category, Alaska operators likely remain exposed to 280E even though they fill medical demand. They do not gain interstate commerce or federal legality either; Schedule III medicalizes and eases research, it does not make a state recreational business federally legal.

Hemp is Alaska's sharpest near-term federal exposure. FY2026 agriculture appropriations (Sec. 781, Rep. Andy Harris, R-MD) narrowed hemp to a total-THC standard (0.3 percent total THC, roughly 0.4 mg THC per container), recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026. The delay bill H.R.7010 was not enacted and the 2026 Farm Bill (H.R.7567) keeps the ban. Alaska already confines intoxicating hemp THC (delta-8, HHC, and similar) to AMCO-licensed marijuana retailers, so the state market is less chaotic than open-hemp states. But the federal cliff still bites: products that previously qualified as "hemp" because they tested under 0.3 percent delta-9 will now fail the total-THC test, so the universe of compounds that can lawfully be produced, imported, or moved as hemp shrinks sharply. The intoxicating-hemp inventory that Alaska routed into dispensaries becomes federally noncompliant hemp, pushing it fully into the controlled-marijuana frame, and out-of-state hemp supply that Alaska retailers and processors relied on can be cut off.

Banking remains unresolved. SAFER Banking stalled in Congress and there is no federal safe harbor; momentum fell further after the Schedule III order took the pressure off. For Alaska this compounds a state-specific squeeze. The residency rule (every owner with a financial interest must be an Alaska resident eligible for the Permanent Fund Dividend) already blocks out-of-state corporate capital and MSO investment. With no federal banking fix and an in-state-only ownership pool, Alaska operators have an unusually thin capital base: they cannot raise outside equity the way operators in non-residency states can, and they cannot rely on normal federal banking. The two constraints stack, leaving small local operators dependent on local lending, cash, and personal capital.

Psychedelics stay Schedule I federally (psilocybin, MDMA, ibogaine). An April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] fast-tracks FDA review, and FDA has issued priority vouchers for psilocybin and methylone, with a Compass psilocybin NDA expected around Q4 2026, but there is no approval yet; conditional federal rescheduling triggers only on FDA approval. This maps neatly onto Alaska's own posture: the HB 228 task force is explicitly scoped to FDA-approved psychedelic medicines, so Alaska's medical pathway is built to switch on if and when the federal FDA pathway delivers an approval. The failed 2026 Natural Medicine Act (now aimed at 2028) sought decriminalization that would run ahead of the federal schedule; absent that, Alaska stays in lockstep with the federal medicalize-on-approval timeline.

Harm reduction is a real exposure given Alaska's rural and tribal health geography. SAMHSA guidance dated April 24, 2026 bars federal funding for fentanyl test strips, clean syringes, and sterile water, with proposed prevention cuts; naloxone is still supported. Alaska distributes very large volumes of naloxone and fentanyl test strips and runs syringe services that are not expressly authorized in statute. The federal restriction threatens the federal-funding stream behind test strips and syringe supplies specifically, which is acute in a state where many services reach rural and Alaska Native communities through federally supported channels (IHS, tribal health organizations, State Opioid Response grants). Naloxone/Project HOPE should be insulated, but the test-strip and syringe components, already on shaky state statutory footing, now also lose their federal funding cover. (Sources: https://www.naco.org/news/samhsa-implements-new-harm-reduction-restrictions-updated-guidance , https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-025-01296-8 , https://www.murkowski.senate.gov/press/release/murkowski-highlights-wide-ranging-wins-for-alaska-in-appropriations-package )

Patient access and rights

This section covers what Alaska law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026.

Hospital access (Ryan's Law): Alaska has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Alaska is not among them. The absence is the finding: an Alaska patient has no enforceable right to use their medicine in a hospital today.

Broader protections: Alaska has had legal adult-use cannabis since 2014, alongside a medical program, but a review of the medical marijuana law (AS 17.37) found none of the six patient protections. The statute expressly declines to require any employment accommodation (AS 17.37.040), and it provides nothing for housing, parenting, an organ transplant list, school enrollment, or general medical care. The absence is the finding: an Alaska patient's legal cannabis use is not shielded in any of these areas.

Out-of-state patients: Alaska does not offer medical reciprocity; its adult-use market serves anyone 21 and older, but an out-of-state medical card carries no patient protections here.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Alaska has not enacted a Ryan's Law. The absence of the broader protections above is a feature of Alaska law, not something federal rescheduling addresses.

Sources: Alaska medical cannabis law, Alaska Statutes Chapter 17.37.

Related reading from Drug Policy Watch: the Federal Drug Policy Brief, the Schedule III rescheduling explainer, and the 50-State Matrix.

Analysis: the enclosure read in depth

Who is fenced out and who consolidates in Alaska is shaped by two opposing forces. On the state side, the residency/Permanent Fund Dividend ownership rule is the dominant anti-enclosure lever in the country's cannabis landscape: by requiring every financial-interest owner to be a roughly one-year Alaska resident, it categorically blocks multi-state operators and out-of-state corporate capital from buying into the market. Combined with no statewide license cap and legal home grow (six plants per adult, twelve per household), the structure keeps ownership local and keeps individuals in the frame. These are genuine commons features. Record sealing via HB 239, now law, adds a modest restorative move, though it is petition-based and narrow.

The fencing pressure is more economic than corporate. The heavy $50 per ounce wholesale cultivation excise squeezes small producers hardest, because a per-ounce tax on flower is regressive against low-margin craft cultivators; it is the single biggest driver pushing consolidation toward whoever can survive thinnest margins, which is why HB 91's proposed cut toward $12.50 per ounce matters as a counter-move. The intoxicating-hemp channeling rule fences out general hemp and CBD sellers while protecting incumbent dispensaries, a smaller, sector-specific enclosure. So within Alaska, enclosure is real but localized: it sorts winners and losers among in-state operators rather than handing the market to national chains.

The state-plus-federal interaction is where the enclosure logic sharpens. Federally, the 2026 reform pattern (Schedule III for medical only, 280E relief for medical only, the hemp total-THC ban, stalled banking, medicalize-on-FDA-approval for psychedelics) favors large, compliance-heavy incumbents: MSOs, pharma, and banks. Alaska is partly insulated from the MSO half of that because the residency rule keeps MSOs out regardless of what the DEA does. But Alaska is fully exposed to the other half: its recreational-structured operators get no 280E relief, its operators get no federal banking and cannot raise outside capital to compensate (the residency rule that blocks MSOs also blocks rescue equity), and its hemp sector faces the November 12, 2026 cliff. The federal hemp ban and the loss of harm-reduction funding fence out exactly the small and informal actors the federal enclosure read predicts: informal hemp producers, general retailers, and harm-reduction programs serving rural and tribal populations.

What to watch: whether HB 91 actually becomes law and cuts the cultivation tax (the most consequential domestic counter-move against small-producer enclosure); implementation of HB 239 record sealing, now law; any AMCO conforming action after the November 12, 2026 federal hemp redefinition; whether the DEA rescheduling hearing produces anything that would reach recreational cannabis (which is what Alaska's market actually is) rather than the medical-only relief already granted; and whether Alaska finds state funding to backfill the harm-reduction supplies SAMHSA will no longer cover.

Justifying the score: Alaska earns a low-to-moderate 2 out of 5. The residency rule and the absence of license caps are unusually strong anti-consolidation features that neutralize the MSO and corporate-capital vector that drives enclosure in most states, and home grow plus pending record sealing keep individuals and the commons in the picture. That keeps the score below the midpoint. It is not a 1 because real fencing pressures exist and are intensifying: the regressive $50 per ounce producer tax squeezes craft cultivators, the hemp channeling rule plus the federal total-THC ban fence out hemp and general retailers, the recreational structure denies operators the new federal 280E relief, and stalled banking interacts with the residency rule to starve local operators of capital with no outside-equity escape valve. The federal layer pushes the pressure up rather than down, but Alaska's structural defenses against corporate consolidation hold the overall read at 2 out of 5. Enclosure pressure score: 2/5.

Active legislation (2026)

This list covers significant bills and is not exhaustive. For the full set and live status, track the Alaska Legislature (https://www.akleg.gov/), LegiScan (https://legiscan.com/AK).

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

  • HB 228 Established Alaska task force on FDA-approved psychedelic medicines (enacted 2024; task force ongoing into 2026) (Enacted 2024; task force active)
Bill Title/Topic Chamber Status Sponsor(s)
HB 91 Marijuana tax reform: phase down $50/oz cultivation excise (to roughly $12.50/oz starting July 2026) and transition toward a 6% retail sales tax House Passed House; advanced toward Rules/Senate; not confirmed signed into law as of mid-June 2026 (one secondary source claims enacted, unconfirmed) Rep. Ashley Carrick (D, Fairbanks)
HB 239 Omnibus crime/public safety bill; includes provision sealing/withholding public release of qualifying low-level marijuana possession convictions (the former HB 81 concept) House/Senate Passed Senate 20-0 (May 19) and House 39-1 (May 20); sent to governor. Update, July 18, 2026: HB 239 became law without Governor Dunleavy’s signature on approximately June 25, 2026, so the marijuana record-sealing provision is now enacted. (source) Omnibus package; marijuana-records concept originated with Rep. David Nelson (R) via HB 81 (sponsor link unconfirmed for final HB 239 text)
HB 81 Standalone marijuana record privacy/sealing bill (concept absorbed into HB 239) House Cleared House Judiciary; substance moved via HB 239; standalone bill effectively superseded Rep. David Nelson (R)
HB 228 Established Alaska task force on FDA-approved psychedelic medicines (enacted 2024; task force ongoing into 2026) House Enacted 2024; task force active Unconfirmed

(Sources: https://www.akleg.gov/basis/Bill/Detail?Root=HB++91 , https://legiscan.com/AK/bill/HB91/2025 , https://alaskabeacon.com/briefs/alaska-house-approves-marijuana-tax-reform-advancing-bill-to-senate/ , https://www.marijuanamoment.net/alaska-bill-to-let-people-seal-their-marijuana-convictions-heads-to-governor , https://norml.org/blog/2026/06/02/alaska-lawmakers-send-cannabis-record-sealing-bill-to-governors-desk , https://blog.mpp.org/blog/alaska-bills-to-seal-marijuana-records-and-lower-cannabis-taxes-introduced/ )

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →

Sources